AI Engines For more Details: Perplexity Kagi Labs You
Uric Acid Reduction: Benzbromarone works by decreasing the production of uric acid in the body and increasing its excretion through the urine. By lowering uric acid levels, it helps prevent the formation of uric acid crystals in the joints, reducing the frequency and severity of gout attacks.
Gout Treatment: Benzbromarone is used as a long-term treatment for gout to prevent recurrent attacks and reduce the risk of complications such as joint damage and kidney stones. It is typically prescribed for patients who do not respond adequately to other medications like allopurinol or who experience intolerable side effects from those drugs.
Hyperuricemia: Benzbromarone is also used to treat hyperuricemia (elevated uric acid levels) in patients with conditions such as gout or certain types of kidney stones. By lowering uric acid levels, it helps reduce the risk of developing gout attacks and related complications.
Kidney Stone Prevention: By promoting the excretion of uric acid through the urine, benzbromarone can help prevent the formation of uric acid kidney stones, a common complication of gout and hyperuricemia.
Anti-inflammatory Effects: In addition to its uric acid-lowering properties, benzbromarone may have mild anti-inflammatory effects that help reduce pain, swelling, and inflammation associated with acute gout attacks.
Renal Function Improvement: Some studies suggest that benzbromarone may have beneficial effects on kidney function, particularly in patients with gout-related kidney damage or impaired renal function. It may help improve renal function by reducing uric acid deposition in the kidneys and preventing further kidney damage.
Cardiovascular Health: There is evidence to suggest that lowering uric acid levels with benzbromarone may have cardiovascular benefits, including a reduced risk of cardiovascular events such as heart attacks and strokes. However, more research is needed to confirm these effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | 0.9 | -2 |
| ADHD | 4.6 | 0.9 | 4.11 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2.9 | 0.07 |
| Allergies | 9.1 | 4.5 | 1.02 |
| Allergy to milk products | 1.6 | 1.3 | 0.23 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.1 | 6.7 | 0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.9 | 2 |
| Ankylosing spondylitis | 3.9 | 1.2 | 2.25 |
| Anorexia Nervosa | 1.6 | 2.6 | -0.63 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 5.5 | 1.8 | 2.06 |
| Atherosclerosis | 2.3 | 2.6 | -0.13 |
| Atrial fibrillation | 3.2 | 2.8 | 0.14 |
| Autism | 10.9 | 9.3 | 0.17 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 2.6 | 2.6 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1.7 | 0.3 | 4.67 |
| Cancer (General) | 0.6 | 3.4 | -4.67 |
| Carcinoma | 4.7 | 2.3 | 1.04 |
| Celiac Disease | 2.9 | 2.9 | 0 |
| Cerebral Palsy | 0.8 | 1 | -0.25 |
| Chronic Fatigue Syndrome | 5.4 | 7 | -0.3 |
| Chronic Kidney Disease | 4.6 | 2.6 | 0.77 |
| Chronic Lyme | 0.6 | 0.5 | 0.2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.6 | 1.4 | 0.86 |
| Chronic Urticaria (Hives) | 1.6 | 1.2 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 3.3 | 1.6 | 1.06 |
| Colorectal Cancer | 9.6 | 2.7 | 2.56 |
| Constipation | 1.5 | 1.3 | 0.15 |
| Coronary artery disease | 2.9 | 2.5 | 0.16 |
| COVID-19 | 10.4 | 12.7 | -0.22 |
| Crohn's Disease | 8.7 | 4.7 | 0.85 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 1.1 | 1.6 | -0.45 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 3.6 | 1.1 | 2.27 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 12.4 | 9.1 | 0.36 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 2.6 | -0.3 |
| Endometriosis | 3.1 | 1.9 | 0.63 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.6 | 1.5 | 1.4 |
| erectile dysfunction | 2.3 | 0.3 | 6.67 |
| Fibromyalgia | 3.7 | 1.8 | 1.06 |
| Functional constipation / chronic idiopathic constipation | 6.2 | 4.6 | 0.35 |
| gallstone disease (gsd) | 4 | 1.1 | 2.64 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.9 | 1.33 |
| Generalized anxiety disorder | 3 | 2.2 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 0.8 | 1.25 |
| Graves' disease | 1.3 | 2.7 | -1.08 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 3.4 | 1.2 | 1.83 |
| Heart Failure | 4.4 | 1.9 | 1.32 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1 | 0 | 0 |
| hyperglycemia | 2.3 | 0.9 | 1.56 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.2 | 4.8 | -0.14 |
| Hypothyroidism | 0 | 1 | 0 |
| Hypoxia | 3.2 | 0.9 | 2.56 |
| IgA nephropathy (IgAN) | 1.6 | 3.5 | -1.19 |
| Inflammatory Bowel Disease | 9.9 | 9.9 | 0 |
| Insomnia | 2.2 | 1.6 | 0.38 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 7.7 | 4 | 0.93 |
| ischemic stroke | 2.6 | 1.4 | 0.86 |
| Liver Cirrhosis | 6.8 | 4.2 | 0.62 |
| Long COVID | 7.4 | 7.6 | -0.03 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.5 | 1 | 0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.1 | -0.91 |
| ME/CFS without IBS | 2 | 2.1 | -0.05 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.6 | 2.5 |
| Metabolic Syndrome | 8.5 | 6.9 | 0.23 |
| Mood Disorders | 11.3 | 7.6 | 0.49 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 7.9 | 6.1 | 0.3 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2 | -5.67 |
| Neuropathy (all types) | 0.7 | 2.8 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 4.3 | 0.35 |
| NonCeliac Gluten Sensitivity | 1 | 0.3 | 2.33 |
| Obesity | 11.1 | 9 | 0.23 |
| obsessive-compulsive disorder | 5.5 | 4 | 0.38 |
| Osteoarthritis | 2.5 | 0.9 | 1.78 |
| Osteoporosis | 1.9 | 1 | 0.9 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.2 | 7.4 | 0.24 |
| Polycystic ovary syndrome | 7.6 | 3 | 1.53 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.2 | -0.33 |
| Primary sclerosing cholangitis | 1.8 | 3.2 | -0.78 |
| Psoriasis | 3.6 | 3.1 | 0.16 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.5 | 4.1 | 1.07 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 5.3 | 2.2 | 1.41 |
| scoliosis | 0.8 | 0.6 | 0.33 |
| Sjögren syndrome | 2.3 | 2.4 | -0.04 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 2.9 | 2.5 | 0.16 |
| Systemic Lupus Erythematosus | 4.3 | 2.2 | 0.95 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.9 | |
| Type 1 Diabetes | 5.1 | 3.8 | 0.34 |
| Type 2 Diabetes | 9.6 | 7.4 | 0.3 |
| Ulcerative colitis | 6.1 | 6.4 | -0.05 |
| Unhealthy Ageing | 6.2 | 2.5 | 1.48 |
| Vitiligo | 1.9 | 1.5 | 0.27 |
